A detailed history of Ancora Advisors, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Ancora Advisors, LLC holds 4,005 shares of CRSP stock, worth $178,743. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,005
Previous 3,705 8.1%
Holding current value
$178,743
Previous $200,000 6.0%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$44.62 - $62.75 $13,386 - $18,825
300 Added 8.1%
4,005 $188,000
Q2 2024

Aug 14, 2024

BUY
$51.17 - $68.18 $3,837 - $5,113
75 Added 2.07%
3,705 $200,000
Q1 2024

May 15, 2024

BUY
$60.67 - $89.12 $39,435 - $57,928
650 Added 21.81%
3,630 $247,000
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $63,722 - $119,097
1,650 Added 124.06%
2,980 $186,000
Q3 2023

Nov 14, 2023

BUY
$45.39 - $59.0 $31,773 - $41,300
700 Added 111.11%
1,330 $60,000
Q1 2022

May 16, 2022

SELL
$53.19 - $79.24 $27,977 - $41,680
-526 Reduced 45.5%
630 $40,000
Q1 2022

May 13, 2022

BUY
$53.19 - $79.24 $27,924 - $41,601
525 Added 83.2%
1,156 $141,000
Q4 2021

Feb 14, 2022

SELL
$70.09 - $111.29 $5,256 - $8,346
-75 Reduced 10.62%
631 $48,000
Q3 2021

Nov 15, 2021

SELL
$110.2 - $156.64 $49,590 - $70,488
-450 Reduced 38.93%
706 $79,000
Q1 2021

May 14, 2021

SELL
$110.72 - $210.04 $24,247 - $45,998
-219 Reduced 15.93%
1,156 $141,000
Q4 2020

Feb 12, 2021

BUY
$79.67 - $173.23 $81,661 - $177,560
1,025 Added 292.86%
1,375 $211,000
Q4 2019

Feb 14, 2020

BUY
$36.68 - $73.13 $12,838 - $25,595
350 New
350 $21,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.48B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Ancora Advisors, LLC Portfolio

Follow Ancora Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ancora Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ancora Advisors, LLC with notifications on news.